AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01093612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining method
Description: Correlative studies
Study NCT01093612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01093612 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study NCT03901235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: Suspension of mesenchymal stromal cells for intratissular injection
Study NCT01394458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 % ethanol / 4% sodium citrate catheter locking solution
Description: This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
Study NCT01394458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin 1000 u / ml
Description: In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
Study NCT04771819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWIS
Description: Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
Study NCT04771819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWIS
Description: Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
Study NCT01889511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - texts
Description: Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes.
Study NCT01532882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: tablet, 600mg, PO, 1 tab per day during 28 days
Study NCT01532882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, PO, 1 per day during 28 days
Study NCT00871143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT specific for BDD
Description: This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
Study NCT00871143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non specific CBT
Description: Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
Study NCT00678899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24
Description: Implantation with Nucleus Hybrid L24 cochlear implant
Study NCT00735228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial pancreas
Description: Artificial endocrine pancreas (NIKKISO Company)
Study NCT02938351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
Study NCT03822962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600Mg Tablet
Description: ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
Study NCT03822962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Regimen | Tylenol
Description: Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
Study NCT03822962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Regimen | Tylenol
Description: Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
Study NCT00594633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: donepezil and questionaires
Description: Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
Study NCT04134767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Linkage
Description: Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
Study NCT04134767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Education
Description: Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
Study NCT04186390 — intervention group
Intervention type: OTHER
Intervention: Simulation training in small bowel capsule endoscopy
Description: Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
Study NCT05893212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature based facilitated group intervention
Description: The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
Study NCT05893212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise in group
Description: The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
Study NCT02576990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT00200005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type: Implantable neurostimulator; InterStim
Description: Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
Study NCT01825629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary therapy
Description: Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks.
Study NCT01825629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01551732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: 10 session manualized cognitive behavioral anger control therapy
Study NCT01551732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT with RAGE-Control
Description: 10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
Study NCT00822133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: lidocaine 5%
Study NCT00822133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine cream
Study NCT00822133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-active drug cream
Description: will be put on the skin
Study NCT04392505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Injection
Description: Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
Study NCT03570684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cable Tie
Description: During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
Study NCT03369548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple
Description: 2 Renetta Canada apples and 2 placebo capsules/ day
Study NCT03369548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oats
Description: 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
Study NCT03369548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri NCIMB 30242
Description: 2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
Study NCT03369548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cornflakes
Description: 40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
Study NCT03531424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic guided PCI
Description: Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
Study NCT03531424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented-Reality CTA guided PCI
Description: Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
Study NCT04080804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
Study NCT04080804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
Study NCT04080804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
Study NCT01816750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac GSI
Description: A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
Study NCT01834755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of psychological phenotype
Study NCT01180855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill nightly for 42 nights.
Study NCT01180855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem 8mg
Description: Rozerem 8mg pill, nightly for 42 nights
Study NCT01180855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem 8mg in combination with Multi Component Behavior Therapy
Description: Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
Study NCT00735995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (individual)
Description: The Coping Cat program, 12 weekly sessions, two additional parent meetings
Study NCT00735995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (group)
Description: The Coping Cat program, 12 weekly sessions, two additional parent meetings
Study NCT03177668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YS110
Description: Intravenous administration
Study NCT03364322 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT01981694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
Study NCT01981694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
Study NCT01437826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidants
Description: tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
Study NCT01437826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo had an identical appearance as intervention
Study NCT01532115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg and 800 mg of BIA 9-1067 (single-dose)
Study NCT01532115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose
Study NCT01532115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg moxifloxacin (single-dose)
Study NCT00867438 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sigmoidoscopy
Study NCT00867438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Study NCT02414048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pimonidazole
Description: Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
Study NCT03064516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrown
Description: In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
Study NCT03064516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay and fiber pin
Description: In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
Study NCT01049113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 013105
Description: 2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
Study NCT03341312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03341312 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT00575900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: 12 weeks of dietary intervention
Study NCT00575900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: 12 weeks of dietary intervention
Study NCT01769352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PredA + Kelac
Description: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
Study NCT00255515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: oral
Study NCT00255515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment for schizophrenia
Description: various standard therapies
Study NCT03411590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fortified milk Powder
Description: Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
Study NCT02758002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Firm ablation for transitional AF rotors
Description: Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
Study NCT00952484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: asfotase alfa
Description: 2 mg/kg subcutaneous injection three times per week for 6 months.
Study NCT00952484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: asfotase alfa
Description: 3 mg/kg subcutaneous injection three times per week for 6 months.
Study NCT06113796 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Robotic rectal resection, either sphincter preserving or extirpation
Study NCT01156571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor P2Y12 (platelet) inhibitor
Study NCT01156571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel - 300 or 600 mg (study arm)
Description: Over encapsulated tablets.
Study NCT01156571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg post cangrelor
Description: over-encapsulated clopidogrel (600 mg)
Study NCT03008967 — intervention group
Intervention type: OTHER
Intervention: Arthroplasty and postoperative rehabilitation.
Description: Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.